Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
Silicone Oil Versus Long-acting Gas Tamponade in Proliferative Diabetic Retinopathy Patients With High-grade Vitreoretinal Adhesion Undergoing Vitrectomy

Subjects receiving 16% C3F8 gas tamponade during vitrectomy will have better visual acuity and similar postoperative complications to subjects who receive silicone oil tamponade during

diabetic retinopathy
retinopathy
proliferative diabetic retinopathy
diabetes
postoperative complications
  • 3 views
  • 20 Mar, 2021
  • 1 location
Pars Plana Vitrectomy With Internal Limiting Membrane Peeling Versus Intravitreal Ziv-Aflibercept for Treatment-Na ve Diabetic Macular Edema

Treatment-nave subjects with center-involved diabetic macular edema undergoing pars plana vitrectomy with internal limiting membrane peeling will have similar visual outcomes but better

diabetic retinopathy
retinopathy
macular edema
proliferative diabetic retinopathy
retinal thickening
  • 9 views
  • 21 Mar, 2021
  • 1 location
Comparison of Interval Variation and Dosage in Preoperative Bevacizumab and Ziv-Aflibercept Administration in Proliferative Diabetic Retinopathy Undergoing Vitrectomy

To compare outcomes in subjects receiving different doses and treatment intervals of intravitreal bevacizumab or ziv-aflibercept preoperatively administered prior to undergoing vitrectomy for

diabetic retinopathy
retinopathy
proliferative diabetic retinopathy
bevacizumab
aflibercept
  • 63 views
  • 25 Jan, 2021
  • 1 location
Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy

Subject/Participant Groups: Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group

diabetic retinopathy
detachment
retinopathy
retinal detachment
proliferative diabetic retinopathy
  • 10 views
  • 18 Mar, 2021
  • 1 location
Combined Antioxidant Therapy on Oxidative Stress in Aqueous and Vitreous Humor of Diabetic Retinopathy Patients

evaluate 56 patients with proliferative diabetic retinopathy undergoing the vitrectomy procedure, who will be assigned to a placebo group or combination antioxidant therapy. Each group will receive the

diabetic retinopathy
detachment
retinopathy
proliferative diabetic retinopathy
glycosylated hemoglobin
  • 1 views
  • 24 Jan, 2021
  • 1 location
Head Positioning After Retina Detachment Repair

inferior retinal breaks after pars that pars plana vitrectomy (PPV) using perfluoropropane (C3F8) gas as a tamponade. The investigator will conduct a single arm phase II study using a Simon's two-stage

  • 5 views
  • 24 Jan, 2021
  • 1 location
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off Rhegmatogenous Retinal Detachment

receive a single intravitreal injection upon diagnosis and enrollment in the study, followed by standard of care surgery. The surgery includes vitrectomy, a procedure that removes the bulk of drug

  • 3 views
  • 16 Feb, 2021
  • 1 location
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

cataract surgery, vitrectomy, glaucoma filtration surgery, intravitreal injections, and other causes include penetrating ocular trauma or from adjacent periocular tissue. Several prophylactic measures have

  • 0 views
  • 26 Jan, 2021
  • 2 locations
Endophthalmitis Post Intravitreal Injections

sequential treatment may equate to more than 1% after 2 years of treatment. Endophthalmitis management following IVIs generally consists of a vitreous tap and inject (TAI) and/or a pars plana vitrectomy (PPV

  • 0 views
  • 02 May, 2021
  • 1 location
Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed …

diabetic retinopathy
retinopathy
bevacizumab
angiogenic factor
anti-vegf therapy
  • 6 views
  • 24 Jan, 2021
  • 1 location